Studying People With Obesity Offered Weight-Loss Medicine
Follows people with obesity who are offered weight-loss medicine.
Plain-language title generated from the registry record
Registry title: Characterization and Phenotyping of Patients Who Are Offered Drug Therapy for Obesity
Key facts
- Where
- Bologna, ItalySee the site
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for people aged 12 or older who have a medical reason to take a drug for obesity: Orlistat, Naltrexone/Bupropion (Mysimba®), Liraglutide (Saxenda®), Semaglutide (Wegovy®) or Tirzepatide (Mounjaro®).
- Age
- 12 years or older
- Sex
- All sexes can join.
- Disease stage
- Obesity with a medical reason to start one of the listed drugs.
Main reasons for not taking part
- Type 1 or type 2 diabetes
- Hypothalamic obesity (inherited or acquired)
- Syndromic obesity, for example Prader-Willi, Alstrom or Bardet Biedl
- Obesity linked to hormone problems, such as Cushing's syndrome or uncompensated hypothyroidism
Read by machine on 9 November 2026.
Where in Italy
- IRCCS Azienda Ospedaliero-Universitaria di BolognaBologna, ItalyContact: Uberto Pagotto, MDTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- IRCCS Azienda Ospedaliero-Universitaria di Bologna
- Trial code
- NCT07414043
- Record updated
- 17 February 2026
- Original description
The study is multicenter and observational, consisting of a cross-sectional phase (V0) in which data will be collected from patients who are offered drug therapy, and a prospective longitudinal phase in which only patients who agree to start drug therapy for obesity will be involvedRead full original descriptionShow less
391/2025/OssF/AOUBo
The study is multicenter and observational, consisting of a cross-sectional phase (V0) in which data will be collected from patients who are offered drug therapy, and a prospective longitudinal phase in which only patients who agree to start drug therapy for obesity will be involved
Inclusion: Therapeutic indication for taking one of the following drugs for the treatment of obesity: Orlistat, Naltrexone/Bupropion (Mysimba®), Liraglutide (Saxenda®), Semaglutide (Wegovy®), Tirzepatide (Mounjaro®).
Exclusion: Endocrinopathies associated with obesity (Cushing's syndrome, uncompensated hypothyroidism); Secondary forms of obesity:; Hypothalamic obesity (both monogenic and acquired forms); Syndromic obesity (e.g., Prader-Willi, Alstrom, Bardet Biedl, etc.).